The Latest Cardiac and Vascular News
Santa Monica, CA, May 06, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical signal processing platform designed to address an unmet technology need for the electrophysiology (EP) marketplace, today announced that the Company conducted patient cases using the PURE EP(tm) System at Indiana […]
WAYNE, Pa., May 06, 2019 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 14, 2019 to shareholders of record at the close of business on […]
SILVER SPRING, Md., May 6, 2019 /PRNewswire/ — On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin‑mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. Vyndaqel and Vyndamax have the […]
MARLBOROUGH, Mass., May 6, 2019 /PRNewswire/ — Boston Scientific (NYSE: BSX) announced today that the U.S Food and Drug Administration (FDA) has approved the VICI VENOUS STENT™ System for the treatment of iliofemoral venous obstructive disease, which occurs when the flow of blood through the veins located deep in the pelvic region becomes blocked […]
VANCOUVER, May 6, 2019 /PRNewswire/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced today that 1,000 patients diagnosed with refractory angina have been […]
SILVER SPRING, Md., May 6, 2019 /PRNewswire/ — On May 3, the U.S. Food and Drug Administration approved Vyndaqel (tafamidis meglumine) and Vyndamax (tafamidis) capsules for the treatment of the heart disease (cardiomyopathy) caused by transthyretin‑mediated amyloidosis (ATTR-CM) in adults. These are the first FDA-approved treatments for ATTR-CM. Vyndaqel and Vyndamax have the […]
SANTA CLARA, California, May 6, 2019 /PRNewswire/ — Based on its recent analysis of the North American remote cardiac monitoring market, Frost & Sullivan recognizes Bardy Diagnostics, Inc. (BardyDx) with the 2019 North America Technology Innovation Award for its Carnation Ambulatory Monitor™ (CAM™) patch. The CAM™ patch is a first-of-its-kind P-wave-centric surface electrocardiograph (ECG) arrhythmia […]
LEUVEN, Belgium and STAMFORD, Conn., May 6, 2019 /PRNewswire/ — LindaCare, a digital health company specializing in development of remote patient monitoring solutions for chronic disease management, announces at the Heart Rhythm Society Scientific Sessions it has added two of the world’s leading experts in cardiac implantable device management to its Medical Advisory Board: Bruce Wilkoff, MD, […]
LAKE OSWEGO, Ore., May 6, 2019 /PRNewswire/ — BIOTRONIK today announced initial enrollment into the BIO-LIBRA study, a first-of-its kind, large-scale prospective study to analyze sex-specific outcomes in patients with non-ischemic cardiomyopathy (NICM) treated with cardiac defibrillator device therapy. To adequately analyze whether women and men respond differently to defibrillator therapy, a minimum of […]
WAYNE, Pa.–(BUSINESS WIRE)–Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, today announced the first commercial use of its Tack Endovascular System in multiple sites across the United States. Recently FDA-approved for above-the-knee interventions, the first-of-its-kind dissection repair device is implanted post-angioplasty to resolve dissections […]
